Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Santa's sleigh or the International Space Station? How to spot a bright Christmas flyby Dec. 24 and 25 - 2Grammy nominations 2026: Full list of nominees in every major category, including Album of the Year and Best New Artist
- 3From Loner to Force to be reckoned with: Individual Accounts of Change
- 4Pulsars to the extreme: Spinning dead stars found blasting radio signals from the 'edge of their magnetic reach'
- 5New movies to watch this weekend: See 'The Drama' in theaters, rent 'Wuthering Heights,' stream 'Pizza Movie' on Hulu
- When the moon hits your eye from your Orion ship up high, that's a 'mare'
- Woman shocked to welcome baby after experiencing stomach pain on Christmas
- Most loved VR Game for Wellness: Which Keeps You Dynamic?
- Mobility exercises are an important part of fitness as we age. Here are some tips
- Most normal matter in the universe isn't found in planets, stars or galaxies – an astronomer explains where it's distributed
- Going with Children: Tips for Tranquil Family Get-aways
- More people are addicted to marijuana, but fewer of them are seeking help, experts say
- Instructions to Plan for Your Teeth Substitution Methodology
- 6 Nations for Setting up camp
